- Pharmaceutical companies
- Biogen
Biogen
Phone: +1 781-464-2000
| Formerly | Biogen Idec Inc. (2003–2015) |
|---|---|
| Type | Public company |
| Traded as |
|
| Industry | Biotechnology |
| Founded | 1978 (1978) |
| Founders | Kenneth Murray Phillip Allen Sharp Walter Gilbert Heinz Schaller Charles Weissmann |
| Headquarters | Cambridge, Massachusetts, U.S. |
| Key people | Stelios Papadopoulos (Chairman) Michel Vounatsos (CEO) |
| Products | Avonex, Fampyra, Plegridy, Tecfidera, Tysabri, Spinraza |
| Revenue | |
| Operating income | |
| Net income | |
| Total assets | |
| Total equity | |
| Number of employees | 9,100 (2020) |
| Website | biogen.com |
At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
For detailed contact information visit location pages below.
Biogen's locations around the world
Europe
North America
Oceania
Clinical Trials sponsored by Biogen
-
BiogenNot yet recruiting
-
BiogenRecruitingPostpartum DepressionUnited States
-
BiogenRecruitingHealthy VolunteerUnited States
-
BiogenRecruitingAmyotrophic Lateral SclerosisChina
-
BiogenRecruitingMuscular Atrophy, SpinalUnited States, China, Japan
-
BiogenRecruitingPrimary Membranous NephropathyAustralia, Taiwan, China, United States, Canada, Japan, Argentina, Brazil, Malaysia, India, South Korea
-
BiogenEnrolling by invitationSubacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus ErythematosusUnited States, Brazil, Spain, Taiwan, Canada, France, Germany, Japan, Italy, Colombia, United Kingdom, Serbia, Chile, Philippines, Bulgaria, China, Sweden, Switzerland, Mexico, South Korea, Argentina, Hungary, Slovakia, Poland, Portugal
-
BiogenCompleted
-
BiogenEnrolling by invitationAntibody-mediated Rejection | Microvascular InflammationUnited States